Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes by Michael A. Lauer, Penny L. Houghtaling, John G. Peterson, Christopher B. Granger, Deepak L. Bhatt, Shelly K. Sapp, Maarten L. Simoons, Robert A. Harrington, Eric J. Topol, and A. Michael Lincoff Circulation Volume 104(23):2772-2777 December 4, 2001 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Rates of death or MI (A), death only (B), and MI only (C) for all patients during heparin infusion and in the 12-hour periods after heparin discontinuation for patients who received placebo (n=3068) or eptifibatide (n=3118). Figure 1. Rates of death or MI (A), death only (B), and MI only (C) for all patients during heparin infusion and in the 12-hour periods after heparin discontinuation for patients who received placebo (n=3068) or eptifibatide (n=3118). Events on heparin therapy were divided by mean hours of therapy for the group and then multiplied by 12 to normalize to events per 12-hour period. Michael A. Lauer et al. Circulation. 2001;104:2772-2777 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Event rates for the subset of patients who were on placebo (n=1537) or eptifibatide (n=1651) at the time of heparin discontinuation. Figure 2. Event rates for the subset of patients who were on placebo (n=1537) or eptifibatide (n=1651) at the time of heparin discontinuation. Event rates on heparin and after its discontinuation are shown as in Figure 1 for death or MI (A), death only (B), and MI only (C). Michael A. Lauer et al. Circulation. 2001;104:2772-2777 Copyright © American Heart Association, Inc. All rights reserved.